• argenx and Zai Lab announce approval of VYVGART® (efgartigimod alfa injection) for generalized myasthenia gravis in China

    Friday June 30th 2023

  • Flen Health receives 1.7 million grant from VLAIO for groundbreaking research on recombinant engineering of wound-healing enzymes

    Monday June 26th 2023

  • argenx announces U.S. Food and Drug Administration approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use in generalized myasthenia gravis

    Wednesday June 21st 2023

  • argenx initiates second cohort of Phase 2 ARDA study of empasiprubart in multifocal motor neuropathy

    Tuesday June 20th 2023

  • Sequana Medical wins Best Technology Award for alfapump® at European Mediscience Awards

    Friday June 16th 2023

  • With the platform Startup.Flanders, Flanders claims its place among international start-up ecosystems

    Friday June 16th 2023

  • Confo Therapeutics enters into research collaboration for GPCR-targeting antibody discovery with AbCellera

    Friday June 16th 2023

  • Biocartis announces planned operational reorganization and cost reduction program

    Friday June 16th 2023

  • Your news here?

  • Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer

    Friday June 16th 2023

  • Mithra announces new positive preclinical data from CSF-1R inhibitor program

    Thursday June 15th 2023

  • My Pathomation new release at the ECDP

    Wednesday June 14th 2023


Strategic Partners